Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Subviral Agents01:29

Subviral Agents

Subviral agents are infectious entities that resemble viruses but lack one or more viral components, such as a capsid or essential replication machinery. These agents include viroids, prions, and satellites, each possessing distinct structural and functional characteristics that influence their mode of infection and replication.Viroids are the simplest subviral agents, consisting of circular, single-stranded RNA molecules without a protein coat. They exclusively infect plants, relying entirely...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Double negative T cells decline in inflammatory reproductive dysfunction.

Scientific reports·2026
Same author

Ovarian localization drives IL-7R-dependent CD8 coreceptor expression in peripheral double-negative T cells.

Cellular and molecular life sciences : CMLS·2026
Same author

HIV-1 uncoating location dictates sites of integration.

Nature communications·2026
Same author

Cytotoxic CD4⁺ T cells exhibit an immunosuppressive shift in checkpoint immunotherapy resistance in melanoma patients.

Cancer immunology, immunotherapy : CII·2025
Same author

Structural investigation of an RNA device that regulates PD-1 expression in mammalian cells.

Nucleic acids research·2025
Same author

Comparative Analyses of Antiviral Potencies of Second-Generation Integrase Strand Transfer Inhibitors (INSTIs) and the Developmental Compound 4d Against a Panel of Integrase Quadruple Mutants.

Viruses·2025
Same journal

Chemotactic self-organization captures the dynamics of mammalian hair follicle patterning.

Proceedings of the National Academy of Sciences of the United States of America·2026
Same journal

Tomographic imaging of superconducting order using particle-hole interference.

Proceedings of the National Academy of Sciences of the United States of America·2026
Same journal

Inhibitory potential of autologous neutralizing antibodies sets quantitative limits on the rebound-competent HIV-1 reservoir.

Proceedings of the National Academy of Sciences of the United States of America·2026
Same journal

Inferring epidemiological parameters under an infectious phylogeography model with visitor dynamics.

Proceedings of the National Academy of Sciences of the United States of America·2026
Same journal

Analytical modeling for suction cup designs for skin-interfaced wearable devices.

Proceedings of the National Academy of Sciences of the United States of America·2026
Same journal

Improving cell-free metabolism through direct integration of artificial respiratory chains.

Proceedings of the National Academy of Sciences of the United States of America·2026
See all related articles

Related Experiment Video

Updated: May 29, 2026

Expression and Purification of Virus-like Particles for Vaccination
06:17

Expression and Purification of Virus-like Particles for Vaccination

Published on: June 2, 2016

Protein delivery using engineered virus-like particles.

Stanislaw J Kaczmarczyk1, Kalavathy Sitaraman, Howard A Young

  • 1Protein Expression Laboratory, Advanced Technology Program, Science Applications International Corporation-Frederick, Inc, Frederick, MD 21702, USA.

Proceedings of the National Academy of Sciences of the United States of America
|September 28, 2011
PubMed
Summary
This summary is machine-generated.

Researchers developed virus-like particles (VLPs) from avian retroviruses as a safe protein delivery system. These adaptable VLPs overcome limitations of current methods, enabling efficient intracellular and surface protein delivery with demonstrated activity in cells.

More Related Videos

Delivery of the Cas9/sgRNA Ribonucleoprotein Complex in Immortalized and Primary Cells via Virus-like Particles ("Nanoblades")
09:23

Delivery of the Cas9/sgRNA Ribonucleoprotein Complex in Immortalized and Primary Cells via Virus-like Particles ("Nanoblades")

Published on: March 31, 2021

Surface Functionalization of Hepatitis E Virus Nanoparticles Using Chemical Conjugation Methods
09:12

Surface Functionalization of Hepatitis E Virus Nanoparticles Using Chemical Conjugation Methods

Published on: May 11, 2018

Related Experiment Videos

Last Updated: May 29, 2026

Expression and Purification of Virus-like Particles for Vaccination
06:17

Expression and Purification of Virus-like Particles for Vaccination

Published on: June 2, 2016

Delivery of the Cas9/sgRNA Ribonucleoprotein Complex in Immortalized and Primary Cells via Virus-like Particles ("Nanoblades")
09:23

Delivery of the Cas9/sgRNA Ribonucleoprotein Complex in Immortalized and Primary Cells via Virus-like Particles ("Nanoblades")

Published on: March 31, 2021

Surface Functionalization of Hepatitis E Virus Nanoparticles Using Chemical Conjugation Methods
09:12

Surface Functionalization of Hepatitis E Virus Nanoparticles Using Chemical Conjugation Methods

Published on: May 11, 2018

Area of Science:

  • Biotechnology
  • Molecular Biology
  • Cell Biology

Background:

  • Existing macromolecule delivery methods face challenges like inefficient uptake and endosomal entrapment.
  • Retroviral vectors for gene delivery pose risks due to host genome integration.

Purpose of the Study:

  • To develop a safe and adaptable alternative for protein delivery into living cells.
  • To demonstrate the efficacy of virus-like particles (VLPs) for intracellular and surface protein delivery.

Main Methods:

  • Utilized virus-like particles (VLPs) derived from avian retroviruses.
  • Engineered VLPs for intracellular delivery via Gag fusion proteins (e.g., Gag-Cre recombinase).
  • Engineered VLPs for surface display of proteins (e.g., murine IFN-γ, human TNF-related apoptosis-inducing ligand).

Main Results:

  • Demonstrated functional activity of encapsidated proteins (Gag-Cre, Gag-Fcy::Fur, Gag-human caspase-8) within recipient cells.
  • Showcased successful surface display of bioactive proteins on VLPs.
  • Confirmed VLP-mediated cellular responses, including STAT1 phosphorylation and induction of cell death.

Conclusions:

  • Avian retrovirus-derived VLPs offer a versatile and safe platform for protein delivery.
  • VLPs can be engineered for both intracellular and surface protein delivery, overcoming limitations of existing methods.
  • This VLP system shows promise for various biotechnological and therapeutic applications.